Intranasal lidocaine for acute migraine: A protocol for the systematic review of randomized clinical trials

Pei Wen Chi, Kun Yi Hsieh, Chien Wei Tsai, Chin Wang Hsu, Chyi Huey Bai, Chiehfeng Chen, Yuan Pin Hsu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

BACKGROUND: Intranasal lidocaine has been shown to be effective in treating patients with acute migraines; however, its efficacy is still controversial. The aim of our study is to assess the efficacy and safety of intranasal lidocaine compared with a placebo or an active comparator for the treatment of acute migraine. METHODS: We will use PubMed, EMBASE, Cochrane library, and Scopus databases to search for articles from their inceptions to November 2018. We will only include randomized controlled studies. Data were independently will be extracted by 2 reviewers. Data analysis and synthesis will be analyzed by the Revman 5.3 software. We will conduct the study in accordance with the guideline of the Preferred Reporting Items for Systematic Review and Meta-analysis Protocols. RESULTS: This review will evaluate the efficacy and safety of intranasal lidocaine for acute migraine. The primary outcome is pain intensity measured by visual analogue, numerical rating scale, or verbal rating scale. Secondary outcomes are success rate, requirement of rescue medicine, relapse, and adverse events. CONCLUSION: The findings of this systematic review will summarize the latest evidence of intranasal lidocaine for acute migraine. The results will provide implications for clinical practice and further research.Prospero registration number: CRD42018116226.

Original languageEnglish
Pages (from-to)e15699
JournalMedicine
Volume98
Issue number20
DOIs
Publication statusPublished - May 1 2019

Fingerprint

Lidocaine
Migraine Disorders
Randomized Controlled Trials
Safety
PubMed
Libraries
Meta-Analysis
Software
Placebos
Medicine
Databases
Guidelines
Recurrence
Pain
Research
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Intranasal lidocaine for acute migraine : A protocol for the systematic review of randomized clinical trials. / Chi, Pei Wen; Hsieh, Kun Yi; Tsai, Chien Wei; Hsu, Chin Wang; Bai, Chyi Huey; Chen, Chiehfeng; Hsu, Yuan Pin.

In: Medicine, Vol. 98, No. 20, 01.05.2019, p. e15699.

Research output: Contribution to journalArticle

Chi, Pei Wen ; Hsieh, Kun Yi ; Tsai, Chien Wei ; Hsu, Chin Wang ; Bai, Chyi Huey ; Chen, Chiehfeng ; Hsu, Yuan Pin. / Intranasal lidocaine for acute migraine : A protocol for the systematic review of randomized clinical trials. In: Medicine. 2019 ; Vol. 98, No. 20. pp. e15699.
@article{68ba86abb9d84b36a019b532fb8a3fae,
title = "Intranasal lidocaine for acute migraine: A protocol for the systematic review of randomized clinical trials",
abstract = "BACKGROUND: Intranasal lidocaine has been shown to be effective in treating patients with acute migraines; however, its efficacy is still controversial. The aim of our study is to assess the efficacy and safety of intranasal lidocaine compared with a placebo or an active comparator for the treatment of acute migraine. METHODS: We will use PubMed, EMBASE, Cochrane library, and Scopus databases to search for articles from their inceptions to November 2018. We will only include randomized controlled studies. Data were independently will be extracted by 2 reviewers. Data analysis and synthesis will be analyzed by the Revman 5.3 software. We will conduct the study in accordance with the guideline of the Preferred Reporting Items for Systematic Review and Meta-analysis Protocols. RESULTS: This review will evaluate the efficacy and safety of intranasal lidocaine for acute migraine. The primary outcome is pain intensity measured by visual analogue, numerical rating scale, or verbal rating scale. Secondary outcomes are success rate, requirement of rescue medicine, relapse, and adverse events. CONCLUSION: The findings of this systematic review will summarize the latest evidence of intranasal lidocaine for acute migraine. The results will provide implications for clinical practice and further research.Prospero registration number: CRD42018116226.",
author = "Chi, {Pei Wen} and Hsieh, {Kun Yi} and Tsai, {Chien Wei} and Hsu, {Chin Wang} and Bai, {Chyi Huey} and Chiehfeng Chen and Hsu, {Yuan Pin}",
year = "2019",
month = "5",
day = "1",
doi = "10.1097/MD.0000000000015699",
language = "English",
volume = "98",
pages = "e15699",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "20",

}

TY - JOUR

T1 - Intranasal lidocaine for acute migraine

T2 - A protocol for the systematic review of randomized clinical trials

AU - Chi, Pei Wen

AU - Hsieh, Kun Yi

AU - Tsai, Chien Wei

AU - Hsu, Chin Wang

AU - Bai, Chyi Huey

AU - Chen, Chiehfeng

AU - Hsu, Yuan Pin

PY - 2019/5/1

Y1 - 2019/5/1

N2 - BACKGROUND: Intranasal lidocaine has been shown to be effective in treating patients with acute migraines; however, its efficacy is still controversial. The aim of our study is to assess the efficacy and safety of intranasal lidocaine compared with a placebo or an active comparator for the treatment of acute migraine. METHODS: We will use PubMed, EMBASE, Cochrane library, and Scopus databases to search for articles from their inceptions to November 2018. We will only include randomized controlled studies. Data were independently will be extracted by 2 reviewers. Data analysis and synthesis will be analyzed by the Revman 5.3 software. We will conduct the study in accordance with the guideline of the Preferred Reporting Items for Systematic Review and Meta-analysis Protocols. RESULTS: This review will evaluate the efficacy and safety of intranasal lidocaine for acute migraine. The primary outcome is pain intensity measured by visual analogue, numerical rating scale, or verbal rating scale. Secondary outcomes are success rate, requirement of rescue medicine, relapse, and adverse events. CONCLUSION: The findings of this systematic review will summarize the latest evidence of intranasal lidocaine for acute migraine. The results will provide implications for clinical practice and further research.Prospero registration number: CRD42018116226.

AB - BACKGROUND: Intranasal lidocaine has been shown to be effective in treating patients with acute migraines; however, its efficacy is still controversial. The aim of our study is to assess the efficacy and safety of intranasal lidocaine compared with a placebo or an active comparator for the treatment of acute migraine. METHODS: We will use PubMed, EMBASE, Cochrane library, and Scopus databases to search for articles from their inceptions to November 2018. We will only include randomized controlled studies. Data were independently will be extracted by 2 reviewers. Data analysis and synthesis will be analyzed by the Revman 5.3 software. We will conduct the study in accordance with the guideline of the Preferred Reporting Items for Systematic Review and Meta-analysis Protocols. RESULTS: This review will evaluate the efficacy and safety of intranasal lidocaine for acute migraine. The primary outcome is pain intensity measured by visual analogue, numerical rating scale, or verbal rating scale. Secondary outcomes are success rate, requirement of rescue medicine, relapse, and adverse events. CONCLUSION: The findings of this systematic review will summarize the latest evidence of intranasal lidocaine for acute migraine. The results will provide implications for clinical practice and further research.Prospero registration number: CRD42018116226.

UR - http://www.scopus.com/inward/record.url?scp=85066838107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066838107&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000015699

DO - 10.1097/MD.0000000000015699

M3 - Article

C2 - 31096514

AN - SCOPUS:85066838107

VL - 98

SP - e15699

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 20

ER -